The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...

Our furry friends may be part of the family, but their digestive systems are not like ours. While some foods are safe and ...

Regenxbio (RGNX) hit by FDA CRL for RGX-121; valuation discount, cash runway to 2027, risks vs RGX-202 upside. Click here to ...

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...

It’s the most common ailment for this organ in the country, but treatment is limited to diet and exercise. Researchers are ...

Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...

A woman whose son was stillborn has said her severe symptoms were dismissed as “nothing to worry about” by NHS hospital staff but she “still feels like a mother despite it all”. Natasha Anderson, 34, ...

Global Heparin Market OverviewThe Global Heparin Market is projected to grow steadily at a CAGR of approximately 5% by 2026.

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...